Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

p38 MAPK inhibition: A promising therapeutic approach for COVID-19

Joseph M. Grimesa, Kevin V. Grimesb,

a Vagelos College of Physicians And Surgeons, Columbia University; 630 W. 168th St, New York, NY 10032, United States of America
b Chemical and Systems Biology, Stanford University, Stanford, CA; 269 Campus Drive CCSR 3145, Stanford, CA 94305, United States of America

ARTICLE INFO

Keywords:
p38 MAPK
COVID-19
SARS-CoV-2
ACE2

ABSTRACT

COVID-19, caused by the SARS-CoV-2 virus, is a major source of morbidity and mortality due to its inflammatory effects in the lungs and heart. The p38 MAPK pathway plays a crucial role in the release of pro-inflammatory cytokines such as IL-6 and has been implicated in acute lung injury and myocardial dysfunction. The overwhelming inflammatory response in COVID-19 infection may be caused by disproportionately upregulated p38 activity, explained by two mechanisms. First, angiotensin-converting enzyme 2 (ACE2) activity is lost during SARS-CoV-2 viral entry. ACE2 is highly expressed in the lungs and heart and converts Angiotensin II into Angiotensin 1–7. Angiotensin II signals pro-inflammatory, pro-vasoconstrictive, pro-thrombotic activity through p38 MAPK activation, which is countered by Angiotensin 1–7 downregulation of p38 activity. Loss of ACE2 upon viral entry may tip the balance towards destructive p38 signaling through Angiotensin II. Second, SARS-CoV was previously shown to directly upregulate p38 activity via a viral protein, similar to other RNA respiratory viruses that may hijack p38 activity to promote replication. Given the homology between SARS-CoV and SARS-CoV-2, the latter may employ a similar mechanism. Thus, SARS-CoV-2 may induce overwhelming inflammation by directly activating p38 and downregulating a key inhibitory pathway, while simultaneously taking advantage of p38 activity to replicate. Therapeutic inhibition of p38 could therefore attenuate COVID-19 infection. Interestingly, a prior preclinical study showed protective effects of p38 inhibition in a SARS-CoV mouse model. A number of p38 inhibitors are in the clinical stage and should be considered for clinical trials in serious COVID-19 infection.

1. Introduction

The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, has resulted in substantial ICU admissions and excess mortality worldwide. Similar to the SARS-CoV virus implicated in the 2003 SARS outbreak, SARS-CoV-2 facilitates cell entry by attaching to angiotensin converting enzyme 2 (ACE2) located on the cell surface [1]. ACE2 is present in multiple tissues and is highly expressed in the lungs and heart [2]. Given this distribution, it is unsurprising that Acute Respiratory Distress Syndrome (ARDS) and myocarditis are the primary causes of death in COVID-19 patients [3]. The cause of overwhelming inflammation induced by SARS-CoV-2 is unclear, however. One particular pathway that has been previously implicated in animal models of acute lung injury and myocardial injury is the p38 MAPK system [4,5]. Upregulation of the p38 MAPK pathway activates pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β [6]. Herein, we argue that the inflammatory injury provoked by SARS-CoV-2 may be due to a disproportionate upregulation of p38 MAPK activity. This inflammation may be attenuated by p38 small molecule inhibitors, many of which have been safely studied in clinical trials for other indications.

2. p38 activation in SARS-CoV-2: The perfect storm

Like SARS-CoV, SARS-CoV-2 binds and downregulates ACE2 upon cell entry [7]. ACE2 converts Angiotensin II (Ang II) into Angiotensin 1–7 (Ang 1–7), which then binds to the Mas receptor to counterbalance the vasoconstrictive and pro-inflammatory effects of Ang II [8,9]. Ang II mediates its effects through p38 MAPK activation [10]. Ang 1–7 stimulation of the Mas receptor decreases p38 MAPK activation to attenuate inflammation [11]. The loss of ACE2 activity upon viral entry may therefore allow Ang II mediated activation of p38 to predominate in the lungs and heart as Ang 1–7 is downregulated. This allows unchecked inflammation and produces a positive feedback loop as p38 activation also upregulates ADAM17, a protease known to cleave the ACE2 ectodomain to further reduce local ACE2 protective activity [12]. It is worth noting that while the role of the renin-angiotensin system (RAS) is still being fully elucidated in the pathogenesis of SARS-CoV-2, a recent study found that inhibition of RAS via angiotensin-converting...
enzyme inhibitors or angiotensin receptor blockers may reduce all-cause mortality in COVID-19 patients [13]. In another study of COVID-19 patients, Ang II levels were linearly associated with degree of lung injury and viral load, further implicating RAS imbalance in the COVID-19 pathogenesis [14].

Furthermore, the previous SARS-CoV virus was shown to express a protein that directly upregulates p38 MAPK in vitro, a pathogenic step thought to be utilized in the lifecycle of many RNA respiratory viruses, including influenza strains associated with severe inflammatory responses such as H5N1 [15,16]. It has been suggested that, among other functions, viral p38 MAPK activation induces endocytosis of viral receptors to facilitate cell entry [17]. Interestingly, p38 MAPK activation has been implicated in the endocytosis of ACE2 [18,32,33]. Given its homology to SARS-CoV, SARS-CoV-2 could use a similar mechanism to directly upregulate p38 MAPK, and a recent study notes that SARS-CoV-2 activates p38 MAPK activity in vitro but does not speculate on the mechanism of increased activity [34]. Thus, SARS-CoV-2 could be propagating severe inflammation and organ damage by both directly upregulating p38 MAPK activity and downregulating a key p38 MAPK shut-off mechanism by reducing ACE2 activity. Furthermore, p38 MAPK activation could simultaneously be propagating the SARS-CoV-2 viral lifecycle. Interestingly, a small preclinical study with a p38 inhibitor in SARS-CoV-infected mice showed 80% survival in the treatment group (N = 5) and 0% in the control (N = 5) [19].

Importantly, overactivation of p38 MAPK activity can also explain additional clinical findings in patients with SARS-CoV-2 infection. There are reports of significant thrombotic events in severely ill COVID-19 patients, and a recent study in COVID-19 patients notes that the vascular endothelium is directly infected in target organs of SARS-CoV-2 [20–22]. Elevated p38 MAPK activity in the endothelium has been implicated in platelet aggregation, arterial thrombosis, and apoptosis of endothelial cells, a clinical finding also shown in the histology of the aforementioned study [23]. Cardiac dysfunction in COVID-19 patients could partly be due to this endothelial dysfunction, or due to overactivation of p38 MAPK in infected cardiomyocytes, which has been shown to induce apoptosis, impair contractility, and increase fibrosis [24]. Additionally, elevated p38 MAPK levels are implicated in hypoxic pulmonary vasconstriction and vascular remodeling, which are poor predictors of outcome in acute lung injury [25,26]. These effects are not entirely unexpected as excessive Ang II signaling, which transmits through p38 MAPK, also produces similar effects. However, in this instance, both direct viral activation of p38 MAPK and overactive Ang II p38 signaling may combine to create severe clinical complications.

3. Implications for therapy

A number of direct p38 MAPK inhibitors are in clinical trials for other indications and could be repurposed for randomized, controlled trials (RCT) in patients at risk for serious COVID-19 infection. Losmapimod is the most clinically studied p38 inhibitor and has a favorable safety profile. In 12 healthy volunteers, a single IV infusion of 3 mg of losmapimod and a subsequent 15 mg oral dose were safe and well-tolerated. Headache was the only adverse event reported more than once. Also reported were nausea, fatigue, dry mouth, neuralgia and nasopharyngitis. Nausea was the only adverse event thought to be drug related [27]. In a 28-day RCT comparing 7.5 mg of losmapimod twice daily versus placebo in hypercholesterolemic patients, losmapimod was well-tolerated and safe in 27 patients, with no serious adverse events. The most commonly reported side effect was headache and there were no differences between treatment groups in other safety data—labs, vital signs, and ECG—including liver function tests [28]. In a 12-week RCT of 7.5 mg of losmapimod twice daily in 3503 patients previously hospitalized with acute myocardial infarction, 16% of the 1738 patients in the on-treatment group experienced serious adverse events compared to 14.2% in the placebo group, requiring study drug discontinuation in 4.4% of on-drug patients and 3.9% of placebo patients [29]. Dilmapimod is another p38 inhibitor previously studied in 77 patients at risk of acute lung injury following trauma in a clinical trial with no relevant safety findings [30]. Various other p38 MAPK inhibitors are currently in clinical trials for a range of indications.

4. Conclusions

The p38 MAPK pathway is a key mediator of inflammation implicated in lung and heart injury. The SARS-CoV-2 virus, like SARS-CoV and other RNA respiratory viruses, may directly upregulate p38 MAPK, perhaps for replication purposes. However, the unique viral entry mechanism of SARS-CoV-2 disables a key counterbalancing mechanism employed by the cell to dampen p38 signaling through ACE2 activity. This combination may allow unrestrained p38 MAPK activity, promoting inflammation, vasocostriction, and thrombosis, while simultaneously benefiting the viral lifecycle. As such, p38 MAPK inhibition may be an appropriate treatment for SARS-CoV-2 infection. This is supported by a small preclinical study of SARS-CoV infection in a mouse model. Further preclinical trials should be performed to elucidate the role of p38 activation in animal models of SARS-CoV-2. More importantly, safe and well tolerated p38 MAPK inhibitors that are already in clinical development could be readily repurposed in randomized, controlled trials enrolling patients at risk for serious COVID-19 complications.

Disclosures

No conflicts of interest exist for either author.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

[1] M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Kruger, T. Herrler, S. Erichsen, et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181 (2) (2020) 271–280.
[2] I. Hamming, W. Timens, M.L.C. Bulthuis, A.T. Lely, G.J. Nasiv, H. van Goor, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol. 203 (2004) 631–637.
[3] Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. (2020) 1–3.
[4] W. Fang, S.-X. Cai, C.-L. Wang, X.-X. Sun, K. Li, X.-W. Yan, et al., Modulation of mitogen-activated protein kinase attenuates sepsis-induced acute lung injury in acute respiratory distress syndrome rats, Mol. Med. Rep. 16 (2017) 9652–9658.
[5] Xin L. Ma, Kumar Sanjay, Guo Feng, S. Leudan Calvert, L. Lopez Bernard, A. Christopher Theodore, et al., Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. circulation, Am. Heart Assoc. 99 (1999) 1685–1691.
[6] T. Zurbin, J. Han, Activation and signaling of the p38 MAP kinase pathway, Cell Res. Publ. 15 (2005) 11–18.
[7] Ghebreali Mahmoud, Kaiming Wang, Vivetors Anissa, Nguyen Quynh, Zheng Jiuchang, J. Turner Anthony, et al., Angiotensin converting enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. Circ. Res. (2020), https://doi.org/10.1161/CIRCRESAHA.120.317015 Ahead of Print.
[8] S.D. Crowley, N.P. Rademuller, ImmunoLogic Effects of the Renin-Angiotensin System, J. Am. Soc. Nephrol. JASN. 28 (2017) 1350–1361.
[9] A.S. Silva, B.D. Silveira, A.J. Ferreira, M.M. Trizeira, ACE2, angiotensin-1 (7–17) and Mas receptor axis in inflammation and fibrosis, Br. J. Pharmacol. 169 (2013) 477–492.
[10] Park Joon-Keun, Fischer Robert, Dechand Ralf, Shagdarsuren Erdenechimeg, Gapeljak Andrey, Wellner Maren, et al., P38 Mitogen-activated protein kinase inhibition ameliorates angiotensin II–Induced Target Organ Damage, Hypertens. Am. Heart Assoc. 49 (2007) 481–489.
[11] X. Yu, L. Cui, F. Hou, X. Liu, Y. Yang, W. Wen, et al., Angiotensin-converting enzyme 2-angiotensin (1–42)–Mas axis prevents pancreatic acinar cell inflammatory response via inhibition of the p38 mitogen-activated protein kinase/nuclear factor-kB pathway, Int. J. Mol. Med. 41 (2018) 409–420.
[12] A.J. Scott, K.P. O’Dea, D. O’Callaghan, L. Williams, J.O. Dokpesi, L. Tatton, et al., Reactive Oxygen Species and p38 Mitogen-activated Protein Kinase Mediated Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM-17) Activation in Primary Human Monocytes, J Biol Chem. Am. Soc. Biochem. Mol. Biol. 286 (2011)
Y. Börgeling, M. Schmolke, D. Viemann, C. Nordho

S.A. Kopecky-Bromberg, L. Martinez-Sobrido, P. Palese, 7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 Mitogen-Activated Protein Kinase, J. Virol. Am. Soc. Microbiol. J. 80 (2006) 785–793.

Y. Bürgeiling, M. Schmolke, D. Viemann, C. Nordho, J. Roth, S. Ludwig, Inhibition of p38 Mitogen-activated Protein Kinase Impairs Influenza Virus-induced Primary and Secondary Host Gene Responses and Protects Mice from Lethal H5N1 Infection, J. Biol. Chem. 289 (2014) 13–27.

D. Marchant, G.K. Singhera, S. Utokaparch, T.L. Hackett, J.H. Boyd, Z. Luo, et al., Toll-Like Receptor 4-mediated activation of p38 Mitogen-activated Protein Kinase is a determinant of respiratory virus entry and tropism, J. Virol. 84 (2010) 11259–11273.

L. Xiao, K.K.V. Haack, I.H. Zucker, Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2 signaling, Am. J. Phys. Cell Physiol. 304 (2013) C1073–C1079.

J.M. Jimenez-Guardado, J.L. Nieto-Torres, M.L. DeDiego, J.A. Regla-Nava, R. Fernandez-Delgado, C. Castaño-Rodriguez, et al., The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis, PLoS Pathog. 10 (2014) e1004320.

F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet. Elsevier 395 (2020) 1054–1062.

Y. Zhang, M. Xiao, K. Zhang, P. Xia, W. Cao, W. Jiang, et al., Coagulopathy and anti-phospholipid antibodies in patients with Covid-19, N. Engl. J. Med. 382 (2020) e38.

Z. Varga, A.J. Flammer, P. Steiger, M. Haberecker, R. Andermatt, A.S. Zinkernagel, et al., Endothelial cell infection and endotheliitis in COVID-19, Lancet 395 (2020) 1417–1418.

X. Chen, T. Tao, H. Wang, H. Zhao, L. Lu, F. Wu, Arterial Thrombosis is accompanied by elevated MITOGEN-Activated Protein Kinase (MAPK) and Cyclooxygenase-2 (COX-2) expression via Toll-Like Receptor 4 (TLR-4) Activation by S100A8/A9, Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 24 (2018) 7673–7681.

M.S. Marber, B. Rose, Y. Wang, The p38 mitogen-activated protein kinase pathway—a potential target for intervention in infarction, hypertrophy, and heart failure, J. Mol. Cell. Cardiol. 51 (2011) 485–490.

A.C. Church, D.H. Martin, R. Wadsworth, G. Blyson, A.J. Fisher, D.J. Welsh, et al., The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension, Am. J. Physiol-Lung Cell Mol. Physiol. Am. Physiol. Soc. 309 (2015) L333–L347.

E.D. Morrell, B.M. Tsai, M. Wang, P.R. Cristo, D.R. Meldrum, p38 mitogen-activated protein kinase mediates the sustained phase of hypoxic pulmonary vasoconstriction and plays a role in phase I vasodilation, J. Surg. Res. 134 (2006) 335–341.

A.M. Barbour, L. Sarov-Blat, G. Cai, M.J. Fosler, D.L. Speicher, J. Graggaber, et al., Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers, Br. J. Clin. Pharmacol. 76 (2013) 99–106.

Cheryyan Joseph, Andrew J. Webb, Sarov-Blat Lea, Elkahward Maysson, M.L. Wallace Sharon, Kaisa M. Miki-Petajä, et al., Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide-Mediated Vasodilation and reduces inflammation in Hypercholesterolemia, Circulation. Am. Heart Assoc. 123 (2011) 515–523.

M.L. O’Donoghue, R. Glaser, M.A. Cavender, P.E. Aylward, M.P. Bonaca, A. Budaj, et al., Effect of Losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: A randomized clinical trial, JAMA. Am. Med. Assoc. 315 (2016) 1591–1594.

J.D. Christie, S. Valsef, P.K. Chang, A.K. May, S.R. Gun, S. Yang, et al., A randomized dose-escalation study of the safety and anti-inflammatory activity of the p38 mitogen-activated protein kinase inhibitor dilmapimod in severe trauma subjects at risk for Acute Respiratory Distress Syndrome, Crit. Care Med. 43 (2015) 1859–1869.

Matthew Deshotels, Huijing Xia, Srivinas Siriramula, Eric Lazartigues, Catalin Filipeneanu, Angiotensin-II mediates ACE2 Internalization and Degradation through an Angiotensin-II type I receptor-dependent mechanism, Hypertension 64 (6) (2014) 1368–1375.

V Kova, XR Huang, W Wang, LD Truong, HY Lan, Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway, Am. J. Pathol. 172 (5) (2008) 1174–1183.

Q Ma, W Pan, R Li, B Liu, C Li, Y Xie, et al., Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kB signaling pathway, Pharmacol. Res. (2020), https://doi.org/10.1016/j. phrs.2020.104850 In press.